$2.51
+0.01
(+0.4%)▲
0.4%
Downside
Day's Volatility :0.4%
Upside
0.0%
26.29%
Downside
52 Weeks Volatility :55.42%
Upside
39.52%
Period | Forian Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -8.09% | 6.5% | 0.0% |
6 Months | -6.56% | 7.1% | 0.0% |
1 Year | -18.57% | 9.8% | 0.0% |
3 Years | -79.71% | 14.2% | -20.2% |
Market Capitalization | 78.8M |
Book Value | $0.85 |
Earnings Per Share (EPS) | 0.09 |
PE Ratio | 28.11 |
PEG Ratio | 0.64 |
Wall Street Target Price | 5.0 |
Profit Margin | 16.57% |
Operating Margin TTM | -36.34% |
Return On Assets TTM | -5.5% |
Return On Equity TTM | 11.8% |
Revenue TTM | 20.5M |
Revenue Per Share TTM | 0.65 |
Quarterly Revenue Growth YOY | 0.1% |
Gross Profit TTM | 21.1M |
EBITDA | -4.9M |
Diluted Eps TTM | 0.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.07 |
EPS Estimate Next Year | -0.01 |
EPS Estimate Current Quarter | -0.02 |
EPS Estimate Next Quarter | -0.02 |
What analysts predicted
Upside of 99.2%
FY20 | Y/Y Change | |
---|---|---|
Revenue | 544.9K | - |
Net Income | -5.0M | ↑ 286.13% |
Net Profit Margin | -913.36% | - |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 16.9M | ↑ 2997.93% |
Net Income | -26.6M | ↑ 433.52% |
Net Profit Margin | -157.3% | ↑ 756.06% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 28.0M | ↑ 65.91% |
Net Income | -26.0M | ↓ 2.18% |
Net Profit Margin | -92.74% | ↑ 64.56% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.5M | ↓ 26.87% |
Net Income | -425.2K | ↓ 98.36% |
Net Profit Margin | -2.08% | ↑ 90.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.9M | ↑ 10.14% |
Net Income | -3.6M | ↓ 30.64% |
Net Profit Margin | -45.0% | ↑ 26.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.9M | ↓ 38.38% |
Net Income | -2.2M | ↓ 36.77% |
Net Profit Margin | -46.17% | ↓ 1.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.9M | ↑ 0.48% |
Net Income | -1.1M | ↓ 50.07% |
Net Profit Margin | -22.95% | ↑ 23.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.3M | ↑ 9.3% |
Net Income | 4.3M | ↓ 486.71% |
Net Profit Margin | 81.18% | ↑ 104.13% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.4M | ↑ 0.38% |
Net Income | 1.4M | ↓ 68.01% |
Net Profit Margin | 25.87% | ↓ 55.31% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 4.9M | ↓ 9.16% |
Net Income | -1.2M | ↓ 187.3% |
Net Profit Margin | -24.86% | ↓ 50.73% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 179.0K | - |
Total Liabilities | 460.1K | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 12.6M | ↑ 6911.84% |
Total Liabilities | 1.3M | ↑ 179.79% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 56.8M | ↑ 352.77% |
Total Liabilities | 31.7M | ↑ 2360.41% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 46.3M | ↓ 18.62% |
Total Liabilities | 33.8M | ↑ 6.83% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 59.4M | ↑ 28.36% |
Total Liabilities | 33.2M | ↓ 1.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 46.3M | ↓ 3.83% |
Total Liabilities | 33.8M | ↑ 0.2% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 55.6M | ↑ 20.27% |
Total Liabilities | 35.2M | ↑ 4.11% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 55.3M | ↓ 0.51% |
Total Liabilities | 34.6M | ↓ 1.9% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 58.8M | ↑ 6.22% |
Total Liabilities | 32.1M | ↓ 7.03% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 59.4M | ↑ 0.99% |
Total Liabilities | 33.2M | ↑ 3.33% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 57.5M | ↓ 3.17% |
Total Liabilities | 31.0M | ↓ 6.77% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.0M | - |
Investing Cash Flow | -227.2K | - |
Financing Cash Flow | 1.2M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.3M | ↑ 311.74% |
Investing Cash Flow | -11.4M | ↑ 4918.69% |
Financing Cash Flow | 16.3M | ↑ 1277.67% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.3M | ↑ 305.99% |
Investing Cash Flow | -1.0M | ↓ 91.01% |
Financing Cash Flow | 36.3M | ↑ 122.37% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.8M | ↓ 49.15% |
Investing Cash Flow | -6.5M | ↑ 530.25% |
Financing Cash Flow | -100.5K | ↓ 100.28% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 217.7K | ↓ 106.51% |
Investing Cash Flow | 1.5M | ↓ 120.97% |
Financing Cash Flow | -29.3K | ↑ 123.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.2M | ↓ 664.26% |
Investing Cash Flow | -633.0K | ↓ 140.94% |
Financing Cash Flow | -94.6K | ↑ 222.63% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -248.8K | ↓ 79.75% |
Investing Cash Flow | 2.3M | ↓ 470.34% |
Financing Cash Flow | -32.8K | ↓ 65.37% |
Sell
Neutral
Buy
Forian Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Forian Inc | -0.4% | -6.56% | -18.57% | -79.71% | -89.08% |
![]() Solventum Corp | 13.4% | -16.71% | -16.71% | -16.71% | -16.71% |
![]() Veeva Systems Inc. | 1.24% | -10.63% | -7.18% | -43.19% | 9.43% |
![]() Ge Healthcare Technologies Inc. | 2.46% | 9.25% | 3.22% | 32.12% | 32.12% |
![]() Healthequity Inc | -3.68% | 3.76% | 26.99% | 6.89% | -2.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Forian Inc | 28.11 | 28.11 | 0.64 | -0.07 | 0.12 | -0.05 | NA | 0.85 |
![]() Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
![]() Veeva Systems Inc. | 54.35 | 54.35 | 1.35 | 4.76 | 0.13 | 0.06 | NA | 30.25 |
![]() Ge Healthcare Technologies Inc. | 23.5 | 23.5 | 20.11 | 4.27 | 0.22 | 0.06 | 0.0 | 16.23 |
![]() Healthequity Inc | 85.91 | 85.91 | 2.29 | 2.19 | 0.04 | 0.03 | NA | 24.11 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Forian Inc | Buy | $78.8M | -89.08% | 28.11 | 16.57% |
![]() Solventum Corp | Hold | $10.8B | -16.71% | NA | 15.73% |
![]() Veeva Systems Inc. | Buy | $29.8B | 9.43% | 54.35 | 22.34% |
![]() Ge Healthcare Technologies Inc. | Buy | $36.9B | 32.12% | 23.5 | 8.05% |
![]() Healthequity Inc | Buy | $6.9B | -2.18% | 85.91 | 7.71% |
Insights on Forian Inc
Revenue is down for the last 2 quarters, 5.36M → 4.87M (in $), with an average decrease of 9.2% per quarter
Netprofit is down for the last 3 quarters, 4.34M → -1.21M (in $), with an average decrease of 127.7% per quarter
In the last 1 year, Healthequity Inc has given 27.0% return, outperforming this stock by 45.6%
In the last 3 years, Healthequity Inc has given 6.9% return, outperforming this stock by 86.6%
Oracle Investment Management Inc
Staley Capital Advisers Inc
Vanguard Group Inc
Canton Hathaway, LLC
Geode Capital Management, LLC
Grey Street Capital, LLC
forian provides a unique suite of saas solutions, data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators and regulators.
Organization | Forian Inc |
Employees | 36 |
CEO | Mr. Michael Vesey |
Industry | Technology |